Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Characterization and In-Vitro Assessment of Pathogen Binding Performance of Engineered Mannooligosaccharides for Nutraceutical Application
FY 2021-22
Summary
Infections by pathogenic bacteria present a health challenge to humans and animals, and with the increasing problem of antibiotic resistance, alternative treatments to antibiotics are needed. Engineered nutritional products such as prebiotics may provide a promising solution to the treatment of bacterial infections without the risk of creating antibiotic-resistant species of bacteria. Prebiotics, fibres that are broken down by bacteria in the digestive tract of humans and animals, have potential in treating bacterial infections by encouraging the growth of beneficial bacteria. Some prebiotics, such as mannooligosaccharides, also appear to have the ability to bind pathogenic bacteria, preventing them from creating infections within humans and animals. The ability of prebiotics in binding pathogens is influenced by their chemical structure, such as their size, but little is known about what is the optimal chemical structure of mannooligosaccharides for pathogen binding. My research will explore what mannooligosaccharide structure has the greatest ability to bind pathogenic bacteria. The findings of my research will contribute to a greater understanding of how prebiotic fibres can be used as an alternative to antibiotics. Engineered nutritional products such as prebiotics can promote health in humans and in agriculture by providing a low cost and safe treatment for bacterial infections without the risk of antibiotic resistance.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
467199
Name
Asbury Rachel E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization and In-Vitro Assessment of Pathogen Binding Performance of Engineered Mannooligosaccharides for Nutraceutical Application
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibiotic Resistance; Carbohydrate Chemistry; Food Engineering; Gut Microbiome; Human Nutrition; Mannooligosaccharides; Nutraceuticals; Oligosaccharides; Pathogen Binding; Prebiotics
Abstract
Infections by pathogenic bacteria present a health challenge to humans and animals, and with the increasing problem of antibiotic resistance, alternative treatments to antibiotics are needed. Engineered nutritional products such as prebiotics may provide a promising solution to the treatment of bacterial infections without the risk of creating antibiotic-resistant species of bacteria. Prebiotics, fibres that are broken down by bacteria in the digestive tract of humans and animals, have potential in treating bacterial infections by encouraging the growth of beneficial bacteria. Some prebiotics, such as mannooligosaccharides, also appear to have the ability to bind pathogenic bacteria, preventing them from creating infections within humans and animals. The ability of prebiotics in binding pathogens is influenced by their chemical structure, such as their size, but little is known about what is the optimal chemical structure of mannooligosaccharides for pathogen binding. My research will explore what mannooligosaccharide structure has the greatest ability to bind pathogenic bacteria. The findings of my research will contribute to a greater understanding of how prebiotic fibres can be used as an alternative to antibiotics. Engineered nutritional products such as prebiotics can promote health in humans and in agriculture by providing a low cost and safe treatment for bacterial infections without the risk of antibiotic resistance.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Asbury, Rachel E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~